AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is conducting a Phase II clinical study titled A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer. The study aims to evaluate the efficacy and safety of adding olaparib to the standard chemotherapy regimen of carboplatin and paclitaxel in patients with advanced ovarian cancer.
The intervention being tested is olaparib, a drug administered orally, in combination with intravenous paclitaxel and carboplatin. The purpose is to improve treatment outcomes in patients with platinum-sensitive advanced ovarian cancer.
This interventional study uses a randomized, parallel assignment model with no masking. The primary purpose is treatment, focusing on progression-free survival as the primary outcome measure.
The study began on February 4, 2010, with primary completion in November 2012. The most recent update was submitted on August 4, 2025. These dates indicate the study’s long-term nature and ongoing updates, reflecting its evolving findings.
The update on this study could positively impact AstraZeneca’s stock performance by bolstering investor confidence in its oncology pipeline. As the study progresses, it may influence market dynamics, especially if results show significant improvements over existing treatments, potentially affecting competitors in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.